CME Activity

Add a subscription to complete this activity and earn CME credit.

Sample questions:

Of the acetylcholinesterase inhibitors (AChEIs) that have been marketed in the United States, which of the following is no longer recommended for clinical use?

Which of the following acetylcholinesterase inhibitors (AChEIs) has been postulated to be of greater benefit in the treatment of Alzheimer’s disease because it increases butyrylcholinesterase (BChE) in the hippocampus and cortex while decreasing acetylcholinesterase (AChE) activity?

Which of the following acetylcholinesterase inhibitors (AChEIs) is unique in that it also modulates neuronal nicotinic receptors?